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Summary Immunotargeting of PLAP-expressing tumours was studied for two radioiodinated, highly specific
anti-PLAP monoclonal antibodies, 7E8 and 17E3, differing 10-fold in affinity, as well as for 7E8 F(ab')2
fragments. An anti-CEA monoclonal antibody or anti-CD3 F(ab')2 fragments were used as controls. Specific
and non-specific targeting was examined in nude mice simultaneously grafted with PLAP-positive tumours
derived from M04 1-4 cells, and CEA-positive tumours, derived from 5583-S cells. Results indicated that (1)
M04 1-4 tumours, with a stable expression of PLAP on the plasma membrane, represent a useful new in vivo
model for immunodirected tumour targeting; (2) differences in antibody affinity for PLAP in vitro are not
reflected in antibody avidity for tumour cells in vivo; and (3) excellent selective and specific localisation of the
PLAP-positive tumours is achieved when 7E8 F(ab')2 fragments are used. The high tumour/blood ratios
(10.7± 3.9 at 46 h after injection) were due to a much faster blood clearance of 7E8 F(ab')2 fragments. At this
time point, the mean tumour/non-tumour tissue ratio was as high as 34.5, and the mean specific localisation
index was 29.0. As expected, the F(ab')2 fragments provided high tumour imaging efficiency on gamma camera
recording. These data imply important potentials of the PLAP/anti-PLAP system for immunolocalisation and
therapy in patients, but also emphasise that in vitro criteria alone are not reflected in in vivo tumour
localisation capacities of antibodies.
Placental alkaline phosphatase (PLAP) is present on the
syncytiotrophoblast after the twelfth week of pregnancy and
can be found in trace amounts in normal cervix, thymus,
lung (Goldstein et al., 1982; Nouwen et al., 1986), ovary
and oviduct (Nouwen et al., 1987). The closely related germ
cell alkaline phosphatase (GCAP, formerly PLAP-like AP)
occurs in very small amounts in normal testis (Chang et al.,
1980). Both isoenzymes display a high degree of polymorph-
ism, and phenotypes can be distinguished electrophoretically
(Robson & Harris, 1965) or by their reactivities with mono-
clonal antibodies (Millan & Stigbrand, 1983; Hendrix et al.,
1990). PLAP or GCAP are expressed in large amounts on the
plasma membrane of ovarian tumours and seminomas, from
where they can be released into patient serum in detectable
amounts. Elevated levels of PLAP or GCAP have indeed
been observed in the sera of ovarian cancer and seminoma
patients (De Broe & Pollet, 1988; Koshida & Wahren, 1990).
The aim of this study was to further examine the useful-
ness of PLAP as a target molecule for radioimmunodetection
of tumours using two of our recent anti-PLAP monoclonal
antibodies (7E8 and 17E3) in experimental immunolocalisa-
tion studies. Since PLAP expression of human tumour cells
transplanted in nude mice is known to be subjected to
modulation (Jeppsson et al., 1984), we used a new recom-
binant cell line (MO4 1-4) in which PLAP was constitutively
expressed under the control of the SV40 large T promotor.
Moreover, it has been described that in vitro characteristics
of antibodies do not always correlate with their in vivo
tumour localisation capacities (Pimm et al., 1987; Sakahara
et al., 1988). We therefore also sought to determine if both in
vitro specificity and affinity of the two anti-PLAP antibodies
are reflected in the binding properties of the antibodies to
tumours in vivo. We included an F(ab')2 fragment since it has
been suggested that the use of antibody fragments may im-
prove the localisation of tumours due to faster blood clear-
ance rates and improved tumour penetration (Wahl et al.,
1983; Buchegger et al., 1983; Buchegger et al., 1986; Andrew
et al., 1986).
Materials and methods
Tumour cell lines
M04 1-4 cells originated from virally transformed M04
mouse fibrosarcoma cells (Billiau et al., 1973). Via electro-
poration using a Baekon 2000 advanced gene transfer system
(Baekon Inc., Saratoga, CA), an expression vector of about
11.6 kbases was transfected into these M04 cells. In this
vector, both the cDNA encoding human PLAP type 2 (kind-
ly provided by Dr J. Millan, La Jolla Cancer Research
Foundation, La Jolla, CA) (Millan, 1986), and the neo-gene
were driven by the SV40 early promotor; the dihydrofolate
reductase gene, enabling eventual amplification, was controll-
ed by the adeno 2 major late promoter. SV40 polyadenyla-
tion and termination signals were also provided. Selection of
recombinant M04 1-4 cells was done in the presence of
geneticin (1 mgml 1). Cells were grown in monolayer culture
at 37'C in a humidified atmosphere with 5% CO2 and pas-
saged every 3-4 days in RPMI 1640 medium (Gibco, Paisley,
Scotland, UK), supplemented with 10% FCS. Prior to injec-
tion into nude mice, the cells were cultured in the presence of
geneticin for at least eight passages and harvested at early
confluency. When cultured in the absence of geneticin, PLAP
expression remained stable for at least 20 passages.
5583-S cells were kindly provided by Dr M. Mareel
(Laboratory for Experimental Cancerology, University Hos-
pital, Ghent, Belgium). These cells were established from a
mucinous colonic adenocarcinoma with a high production of
CEA (Verstijnen et al., 1987). The 5583-S cells grow as
multicellular floating spheroids at 37°C, 5% C02, and were
passaged every 3-4 days in DMEM medium (Gibco) con-
taining 15% FCS.
Monoclonal antibodies
The anti-PLAP antibodies 7E8 and 17E3 (both IgGl's) (Hen-
drix et al., 1990) were purified from ascites by PROSEP A
column chromatography (1.5 x 2.8 cm) (Porton, Berkshire,
UK). Affinity constants for the interaction between PLAP
(Type 1) and these antibodies are 9 x 108 M-' and 0.9 x 108
M-1 for 7E8 and 17E3, respectively. The anti-CEA antibody
7F (IgGI) was kindly obtained from Dr J.C. Chan (Univer-
sity of Texas, M.D. Anderson Cancer Center, Houston, T)
and the anti-CD3 antibody OKT3 (IgG2a) and from the
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Ortho Pharmaceutical Corporation (New Brunswick, NJ).
Both 7F and OKT3 were unreactive with PLAP.
Antibodyfragmentation
F(ab')2 fragments of antibodies 7E8 and OKT3 were obtain-
ed by digestion with insolubilised pepsin as recommended by
the manufacturer (Pierce, Rockford, IL). Separation of Fc
and F(ab')2 fragments was performed by chromatography on
Prosep A and by HPLC anion exchange on TSK PW 5
DEAE (Pharmacia, Uppsala, Sweden), monitored by SDS-
PAGE (Laemmli, 1970).
Radiolabelling
Intact antibodies and fragments were radiolabelled with 1251I
(Amersham, Brussels, Belgium) using the chloramine T pro-
cedure (Greenwood et al., 1963) at a molar ratio of
chloramine T/IgG and chloramine T/F(ab')2 of 205 and 148,
respectively. Chromatograms obtained upon gel filtration on
a Sephadex S-300 column (1 x 30cm), equilibrated in PBS
containing 2% BSA, indicated that no antibody aggregation
had occurred during labelling. The labelling efficiency ranged
from 57.8% to 66.2% for intact antibodies, and from 11.8%
to 18.3% for F(ab')2 fragments. The corresponding specific
activities varied from 28.9 to 33.1 mCi mg-' for intact anti-
bodies and from 5.2 to 9.2 mCimg-' for the fragments.
Affinity and immunoreactivity ofantibodies andantibody
fragments before andafter radiolabelling
Competition sandwich ELISA Before labelling, the affinity
of the anti-PLAP antibody 7E8 and its F(ab')2 fragment were
compared in a competition sandwich ELISA in which in-
creasing concentrations (0-167 nM) of intact 7E8 or 7E8
F(ab')2 were allowed to compete with intact, biotin-labelled
7E8 (16.7 nM) for binding to PLAP, immobilised in micro-
titre plates.
Flow cytometry Membrane binding of the intact anti-PLAP
antibodies 7E8 and 17E3, the F(ab')2 fragments of 7E8, the
anti-CEA antibody, and the OKT3 antibody and its frag-
ment with M04 1-4 cells, 5583-S cells, or human peripheral
blood mononuclear cells (PBMCs) was determined by flow
cytometry. PBMCs were prepared from heparinised blood
from a normal donor by Fycoll-Hypaque (Pharmacia) centri-
fugation. M04 1-4 cells, 5583-S cells, and PBMCs were
counted and adjusted to 107 viable cells per ml in HBSS
(Gibco), containing 20% denatured normal horse serum and
0.01% NaN3 and incubated at OC for 1 h upon addition
of antibodies (4gsgml-'). Thereafter, cells were washed
and incubated with a fluorescein-conjugated rabbit anti-
mouse Ig F(ab')2 fragment (Dakopatts, Glostrup, Denmark).
After 1 h at 0°C, cells were washed and analysed in a FACS-
TARPPI" cell sorter (Becton Dickinson Immunocytometry
Systems, Mountain View, CA). Results are expressed as the
mean linear fluorescence intensity from 10,000 cells analysed.
Enzyme Antigen Immunoassay (EAIA) Antigen affinity of
7E8 IgG, 7E8 F(ab')2, or 17E3 IgG was compared before and
after radiolabelling in an in vitro EAIA as described (Hendrix
et al., 1990). Briefly, microtitre plates precoated with rabbit
anti-mouse polyclonal antiserum were saturated with unla-
belled and '25I-labelled intact antibodies or their F(ab')2
fragments. After washing, 2ng (1001tl) of PLAP was incu-
bated overnight at 4°C. The alkaline phosphatase activity
bound to the antibodies (B) and the initial, total activity (T)
were then measured in an EAR Multi-well reader (SLT
Labinstruments, Gr6dig, Austria), and the percentage bind-
ing (B/T x 100) was calculated.
Live cell-binding assay The immunoreactivity of antibody
preparations before and after labelling was also compared in
an in vitro live cell-binding assay. M04 1-4 and 5583-S cells
were suspended at 5 x 106 cellsml-' in PBS in the presence
of antibody (20 ngml-), corresponding to a 10-fold molar
excess of antigen to antibody. Upon incubation at 0°C for
5 h, the cells were pelleted by centrifugation; free and cell-
bound radioactivity were counted in a gamma counter
(Cobra 5005, Packard Instrument Company, Meridan, CT),
and the percentage of bound antibody was calculated. In
addition, free and total antibody concentrations were
measured by standard ELISA procedures, both for unlabell-
ed and labelled preparations.
In vivo tumour model andantibody administration
Ten-week-old female nude mice (Nu/Nu Balb/c NMRI,
Charles River, Wiga, Germany) were injected subcutaneously
with 5 x 105 MO 1-4 cells in the right thigh, and with 107
5583-S cells in the left thigh, respectively, 10 and 13 days
before injection of the radiolabelled antibodies, i.e. to assure
equally sized tumours. Radiolabelled intact antibodies or
fragments were then administered in sterile saline at 151Ci/
mouse for biodistribution studies, and at 150fiCi/mouse for
imaging studies. The nude mice were kept on sterile bedding
with sterilised food and water. Drinking water was supple-
mented with 1 mgml[- KI and 10 mM NaHCO3 throughout
the study.
Biodistribution
Mice, three per antibody group, were bled, sacrified by cer-
vical dislocation, and dissected at various time points after
antibody administration. Tumours and normal tissues (intes-
tines, liver, spleen, kidneys, heart, lung, skeletal muscle, bone
and fat) were removed, rinsed with saline, blotted dry, placed
in counting tubes, and weighed. All samples were then coun-
ted in a gamma counter, correcting for physical decay.
Results oflabelled antibody biodistribution were expressed as
different parameters including:
Accumulation of antibodies in tissues The accumulation
index was defined as Al = % dose injected/g tissue. This
index is an indication of the avidity of an antibody for a
given tissue.
Selectivity of tumour uptake Selective tumour uptake of
the different antibodies was determined by comparing the
tumour/non-tumour ratios found for these antibodies, i.e. the
ratios of activity in tumour to activity in normal, non-
tumour tissues, according to the formula: SI = tumour/non-
tumour tissue = % injected dose per g tumour/% injected
dose per g non-tumour tissue. This ratio was calculated for
nine normal tissues, including kidneys, intestines, liver,
spleen, heart, lung, skeletal muscle, bone and fat tissue. Due
to skewness, means were expressed as geometric means and
the Mann-Whitney U test was used to compare SI's for the
M04 1-4 tumour and the 5583-S tumour. The tumour/kidney
ratio was excluded when mean SI were calculated for the
F(ab')2 fragments.
Specificity of tumour localisation The localisation index (LI)
was defined as the ratio of specific to non-specific antibody
uptake in tumours and other tissues, divided by the same
ratio in the blood (Moshakis et al., 1981): LI = % dose per g
tumour/% dose per g blood (for specific antibody) divided by
% dose per g tumour/% dose per g blood (for non-specific
antibody).
Pharmacokinetic analysis
At each time point, tissue concentrations of radioactive anti-
body (% of injected dose per g tissue) were averaged for
three mice. Data of mean concentration vs time were ana-
lysed by least square nonlinear regression using the BMDP
Statistical Software (Dixon, 1988). When calculated this way,
the a and P elimination rate constants had standard devia-
tions below 10%. The corresponding tissue half-life values
were calculated as t/2 = 0.693/,. The area under the concen-1062 P.G. HENDRIX et al.
tration x time curve (AUC) was determined using the trape-
zoidal rule.
Imaging studies
Scintigraphic imaging was performed at various time points
after antibody administration. Mice were anesthetised with
pentobarbital (Nembutal, Abbott, Ottignies, Belgium; 40 mg
kg-') and imaging was performed using a mobile gamma
camera (Technicare, Sigma 4205, Ohio Nuclear Inc., OH)
equipped with a high resolution, parallel hole collimator.
Analog and digital images were made ventrally, with the
animals positioned directly on the collimator. Images were
acquired for approximately 70,000 counts, resulting in imag-
ing times of 10 to 30 min. Digital images were normalised
using a Sophy P computer (Sopha Medical, Buc, France).
Following final imaging, the mice were dissected and the
radiolabelled antibody distribution was calculated as des-
cribed above.
Histochemical and immunohistochemical studies
M04 1-4 cells and 5583-S cells were stained histologically
and immunohistologically for the presence of PLAP or CEA.
These cells were analysed before injection in mice, after
passage in these mice, or after passage in cell culture (in the
absence of geneticin) for as long as the cells were growing in
the developing tumours. Tumour sections taken at the start
and at the end of the experiment were stained as described
(Nouwen et al., 1987) using a polyclonal anti-PLAP anti-
serum (Analis, Namur, Belgium) and anti-CEA antiserum
(Dakopatts).
Histological staining for PLAP activity was done according
to the method of Gossrau (Gossrau, 1978). To eliminate the
activity of endogenous mouse tissue non-specific AP in
stromal capillaries, the sections were pre-treated by heating
(5 min, 65°C).
Results
Characterisation ofPLAP expressed by recombinant M04 1-4
cells
Before using the PLAP-transfected M04 1-4 tumour cells as
antibody targets in vivo, the PLAP antigen produced by these
cells was fully characterised with respect to its heat stability,
enzyme kinetics, inhibitor sensitivity, reactivity with mono-
clonal antibodies, and electrophoretic mobility in starch gel
or paragon electrophoresis. Essentially, no differences were
detected between the PLAP extracted from M04 1-4 cells
and from placenta, type 2. Immunohistochemical and elec-
tron microscopic observations revealed that PLAP was local-
ised on the external surface of the plasma membrane of all
M04 1-4 cells, although the PLAP expression varied quanti-
tatively between cells.
Tumour growth andantigen expression in growing tumours
One hundred thousand M04 1-4 cells and 107 5583-S cells
were subcutaneously injected in the right and left thighs of
nude mice, respectively. The tumours appeared within 8 days
after injection with an incidence of 100%. There was no
formation of metastases or ascites, not even after 5 weeks.
The amounts of cells injected were adjusted so as to obtain
tumours of comparable size in both thighs during the experi-
ments. The average weight of M04 1-4 and 5583-S tumours
at the onset ofantibody administration was 0.41 ± 0.17 g and
0.49 ± 0.12 g, respectively (n = 15). Microscopically, necrosis
was not seen in tumours of this size.
PLAP activity measurements in M04 1-4 tumour extracts,
as well as histochemical PLAP stainings in tumour tissues
(Figure la,b), showed an abundant PLAP expression on the
plasma membranes of the M04 1-4 tumour cells throughout
the duration of the study, at a fairly constant level of 3.84 ±
Figure 1 Histochemical staining of PLAP activity in M04 14
tumour sections taken at 11 a, or 18 b, days after tumour cell
injection in the thighs of athymic nude mice. Immunohisto-
chemical staining of CEA in 5583-S tumour sections taken at 11
c, or 18 d, days after injection. Control immunohistochemical
staining of M04 14 tumours for CEA expression and staining of
5583-S tumours for PLAP expression were negative (not shown).
Bar, 50tim.
0.76jig g-' tumour (n = 9). Likewise, the 5583-S tumours
showed strong CEA staining on the plasma membranes
(Figure lc,d). Control stainings for PLAP in 5583-S tumours,
and for CEA in M04 1-4 tumours were negative. Histo-
chemical staining of M04 1-4 cells at the moment of injec-
tion, after passage in the nude mice, and compared with cells
kept in culture for an equally long time period without
geneticin confirmed the stability of PLAP expression (data
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Affinity and immunoreactivity ofantibodies and their F(ab')2
fragments
The most intense immunohistochemical staining levels on
non-fixed M04 1-4 cells were obtained using the anti-PLAP
monoclonal antibodies 7E8 and 17E3 (affinity constants of
9 x 108 M and 0.9 x I01 M-I, respectively). A sufficient
amount of F(ab')2 fragments could only be obtained for 7E8
and for the negative control antibody OKT3. The affinity of
antibody 7E8 and its F(ab')2 fragment were compared in a
competition sandwich ELISA: intact 7E8 and 7E8 F(ab')2
competed equally well with biotinylated intact 7E8 for bind-
ing to PLAP.
Immunoreactivity analysis of 7E8 and 7E8 F(ab')2, 7F,
OKT3, and OKT3 F(ab')2 with M04 1-4, 5583-S cells, or
human lymphocytes by indirect immunofluorescence with
fluorescein-conjugated rabbit anti-mouse Ig F(ab')2 fragments
indicated that each antibody reacted specifically with cells
expressing the corresponding antigen and confirmed that 7E8
reacts better with PLAP than 17E3. Reactivities of F(ab')2
fragments corresponded to those of the intact antibodies.
Affinity and immunoreactivity ofradiolabelled antibodies and
F(ab')2fragments
Molar ratios of incorporated 1251I into the antibodies were
maximally 2.9 for intact antibodies and 0.6 for F(ab')2 frag-
ments. Analysis in EAIA indicated no important losses in
affinity after radiolabelling of intact 7E8, 17E3, and 7E8
F(ab')2 (data not shown). Unlabelled as well as radiolabelled
7F IgG and OKT3 F(ab')2 fragments were unreactive with
the PLAP antigen in EAIA. In addition, we compared the
capacity of unlabelled and labelled antibody preparations to
bind to both tumour target cells presenting an excess of
antigen in a live cell-binding assay. Total and unbound
antibody concentrations were determined by standard ELISA
procedures. Also, the ratio c.p.m. cell-bound/c.p.m. added
was calculated for the radiolabelled antibodies. The percen-
tage binding obtained either way was identical, i.e. the intro-
duction of 125I-label in the antibody preparations did not
cause any important loss in immunoreactivity. In addition,
both assays confirmed the higher PLAP binding by 7E8 than
by 17E3.
Biodistribution andpharmacokinetics ofradiolabelled intact
antibodies 7E8, 17E3, and 7F
Anti-PLAP antibodies 7E8 and 17E3, or the anti-CEA anti-
body 7F were injected i.p. as intact antibodies in nude mice,
bearing PLAP-expressing M04 1-4 tumours and CEA-
expressing 5583-S xenografts at contralateral thighs. This
way, we could evaluate the tumour-localising capacities of all
antibodies with built-in reciprocal controls at the level of
tumour type and antibody specificity. Blood, tumours, and
tissues from three animals per group were sampled for weigh-
ing and c.p.m. counting at 6 h, and on day 1, 3, 6, 8, 10 and
13 after injection.
The mean accumulation indices (Al, % of injected dose
per g tissue) for blood, M04 1-4 tumours, 5583-S tumours,
and relevant non-tumour tissues are depicted in a semi-log
plot of concentration vs time (Figure 2a,b,c). Elimination
curves of the iodinated intact antibodies from the blood and
from non-tumour tissues were similar for all three antibodies.
Antibody levels in blood rose to peak levels between 6 h and
24 h at 9.6 to 14.3% ofinjected dose per g blood. Peak tissue
concentrations in antigen-positive tumours occurred on day 1
for 7E8 and 17E3 (3.3 ± 0.5 %/g and 5.0 ± 0.6 %/g, respec-
tively) and on day 6 for 7F (4.0 ± 0.6%/g). In control tumours
and normal tissues, this occurred on day 1 for all the anti-
bodies (between 2 and 3 %/g). For all three antibodies,
antigen-negative control tumour curves were slightly above
the non-tumour tissue curves. For antibody 17E3 a signi-
ficantly higher uptake was observed in the M04 1-4 tumour
as compared to the control tumour on day 1 (P<0.005) and
3 (P<0.05). For antibodies 7E8 and 17E3, blood always
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Figure 2 The mean tissue accumulation (AT) of '25I-labelled
intact antibodies 7E8 E a, 17E3 b, and 7F c, and F(ab')2
fragments of 7E8 d, and OKT3 e, in blood (-A--), M04 14
tumour (-*-), 5583-S tumours ( 0 ), kidney (----x--),
and relevant non-tumour tissues (shaded area). Three animals per
time point were injected i.p. and concentrations of radioactivity
(% injected dose/g) in tumours and tissues were measured.
Results are depicted in a semi-log plot of concentration vs time.
contained a higher concentration than normal or tumour
tissue. In the case of 7F, tumour retention remained high,
and after day 10, the 5583-S tumour curve had even crossed
the blood curve. From day 6 onwards antibody uptake in the
antigen-presenting tumour was significantly higher as com-
pared with the control tumour (P<0.05 until P<0.001).
Pharmacokinetic parameters derived by regression analysis
from the concentration (% of injected dose/g) x time data
are summarised in Table I. For 7E8, no difference in t1/2 was
seen between antigen-expressing tumour, control tumour, or
non-tumour tissue. The AUC value for both tumour types
was identical and slightly higher than for normal tissues.
However, when 17E3 was injected, the AUC for the PLAP
containing M04 1-4 tumour was higher as compared with
the value for the control tumour. For 7F, the t1/2 and AUC
for the CEA-positive tumour were almost twice the value
found for the control tumour.
The selectivity of tumour uptake (SI) was calculated as
tumour vs non-tumour tissue ratios for the antigen-expressing
tumour as well as for the control tumour (data not shown).
When 7E8 was injected, mean SI's ranged between 1.1 and
3.0 for both tumour types and for nine different normal
tissues. Three days after injection of 17E3 a higher mean SI
was found for the M04 1-4 tumour (SI = 4.8; range = 2.3-
11.2), than for the control tumour (SI = 2.6; range 1.2-6.5)
(P= 0.07). After administration of 7F, the mean SI for the
CEA-positive tumour increased progressively to 12.9 (56.2-
45.5) on day 13 after injection, while the ratio for the control
tumour remained 1.7 (0.7-5.9) (P<0.05 from day 6 on-
wards and P<0.001 on day 13).
In Table II localisation indices are calculated for the
antigen-expressing tumours at various time points after anti-
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Table I Pharmacokinetic parameters of '25l-labelled antibodypreparations in xenograft
bearing nude mice
Tissue
t,12 (h) [AUC (% injected dose x h)]
Intact antibodies F(ab')2fragments
7E8 17E3 7F 7E8 OKT3
anti-PLAP anti-PLAP anti-CEA anti-PLAP anti-CD3
Blood
M04 1-4 tumour
5583-S tumour
Intestines
Liver
Spleen
Heart
Lung
Muscle
Bone
Fat
Kidney
62.4 [1272] 72.2 [1431] 106.6 [1561]
79.7 [425] 77.0 [627] 100.4 [503]
79.7 [406] 106.6 [402] 266.0 [900]
55.0 [121] 87.0 [121] 97.6 [143]
67.9 [309] 75.3 [295] 111.8 [338]
50.2 [312] 71.4 [297] 110.0 [366]
73.7 [266] 83.5 [304] 115.5 [344]
68.6 [343] 87.7 [360] 126.0 [424]
62.4 [65] 87.7 [71] N.D. [69]
58.7 [100] 46.2 [103] 96.3 [129]
59.2 [162] 35.0 [224] 165.0 [178]
61.9 [321] 57.8 [313] 88.9 [351]
Table II Localisation indices (LI) for the antigen-expressing tumour
(i.e. M04 1-4 tumour for the anti-PLAP antibodies; 5583-S tumour for
7F)atvarious timepointsafterinjectionoftheradiolabelledantibodies.
LI- = Mean (TUMOUR/BLOOD)* specific antibody
Mean (TUMOUR/BLOOD)* non-specific antibody
For the anti-PLAP antibodies, 7F served as the non-specific antibody,
and for 7F, the anti-PLAP 17E3 was taken as the control antibody.
F(ab')2
Time after antibody Intact antibodies fragments
injection 7E8/7F 17E3/7F 7F/17E3 7E8/OKT3
6 h 1.17 1.22 1.40 2.88
16 h 12.00
26h=day 1 0.82 1.35 1.58 9.12
36 h 16.77
46 h 29.00
76 h = day 3 1.09 1.65 1.42 18.43
day6 1.21 1.15 2.37
day 8 1.43 1.54 2.59
day 10 1.23 1.39 2.57
day 13 1.50 1.69 4.52
*The ratios were calculated from tumour/blood data obtained in
different mice, injected with the antibodies indicated.
body injection. No specific localisation of the M04 1-4
tumour was seen with 7E8 or 17E3. The specificity of 5583-S
tumour localisation by 7F was documented by increasing
indices, up to a mean value of 4.52 at day 13 after antibody
injection.
Biodistribution andpharmacokinetics ofradiolabelled 7E8 and
OKTF(ab')2fragments
We evaluated whether the use of F(ab')2 fragments would
improve the localisation of the PLAP-presenting M04 1-4
tumour. Since pepsin digestion of intact 17E3 turned out to
be unsuccessful, we restricted our analysis to the evaluation
of the specific tumour localisation competence of 7E8 F(ab')2
fragments. OKT3 F(ab')2 was used as non-specific control
fragments and the 5583-S tumour as an antigen-negative
control tumour. Blood, tumour, and tissue sampling was
performed at 6, 16, 26, 36, 46 and 76 h after radiolabelled
antibody injection. Additional blood sampling was done at
0.5, 1, 2 and 4h.
F(ab')2 fragments of 7E8 and OKT3 were eliminated from
the blood and non-tumour tissues at a similar rate: much
faster clearance than was seen for intact antibodies (Figure
2d,e). Antibody fragment levels in blood peaked at 2h at
7.5 ± 0.6% of injected dose per g blood, but already decreas-
ed below 2%/g at the 16th hour. Peak concentrations in
M04 1-4 tumour occurred at 6 h for 7E8 F(ab')2 (6.70 +
0.01%/g) and remained above 1%/g until 46 h after injection.
Peak concentrations in normal tissues were 2.0 ± 0.2%/g at
6 h and already decreased below 0.4%/g at 16h. For the
non-specific OKT3 F(ab')2 fragments, maximum concentra-
4.3
14.0
6.0
4.0
4.6
4.7
4.1
4.7
5.0
5.3
2.7
3.6
[83]
[168]
[29]
[25]
[23]
[24]
[26]
[35]
[6]
[8]
[32]
[162]
5.4
6.0
7.3
3.3
5.4
6.6
4.9
8.9
10.0
4.6
4.3
5.6
[59]
[20]
[24]
[21]
[22]
[21]
[19]
[21]
[5]
[7]
[22]
[99]
tions in tumour and non-tumour tissues were below 2% of
injected dose/g at 6 h and decreased rapidly below 0.5%/g.
Elimination profiles of antibody fragments from the kidneys
were depicted separately since, in contrast to what was found
with intact antibodies, they contained significantly higher
radioactivity concentrations. For 7E8 F(ab')2 fragments, the
M04 1-4 tumour curve was situated above the control
tumour and normal tissue curves from the first time point
onwards (P<0.05 until P<0.001); it crossed the blood
curve already at 6 h and the kidney curve was crossed before
16 h. For the non-specific OKT3 F(ab')2 fragments, no differ-
ence was seen between profiles from PLAP-expressing tumour,
control tumour, and normal tissue; the blood and kidney
curves remained the highest throughout the experiment.
The pharmacokinetic parameters t1/2 and AUC, calculated
for the 7E8 F(ab')2 fragments (Table I), were much higher for
the M04 1-4 tumour, than for blood, control tumour, and
non-tumour tissues. By contrast, all t1/2 and AUC values
were comparable for the clearance of OKT3 F(ab')2. For
both antibody fragments, the kidney AUC was elevated.
While no selective tumour uptake was seen for intact 7E8
antibody, its F(ab')2 fragments showed significantly elevated
tumour/non-tumour tissue ratios for the antigen-presenting
M04 1-4 tumour (Figure 3). Higest selective tumour uptake
was found at 46 h after injection with a geometric mean SI
for eight normal tissues of 34.5 (14.7-118.3). The ratio for
the PLAP-negative 5583-S tumour remained between 1.3 and
2.9 (P<0.001 from 16 h after injection onwards). In Figure
3 selectivity indices are furthermore given in detail for kid-
neys and eight other normal tissues at different time points
after injection of 7E8 F(ab')2. In the control experiment with
OKT3 F(ab')2 fragments, all tumour/non-tumour tissue ratios
were about one (results not shown).
The M04 1-4 tumour localisation by 7E8 F(ab')2 can be
considered specific, since tumour to blood ratios were always
lower for the control OKT3 F(ab')2 fragments than for the
specific 7E8 F(ab')2 fragments. LI values, calculated for 7E8
F(ab')2, using OKT3 F(ab')2 as the non-specific fragment, are
shown in Table II.
Imaging results
Scintigraphic images were obtained on days 6, 8, 10, and 13
after i.p. injection of radiolabelled intact 7F, 7E8, or 17E3 in
nude mice, bearing a M04 1-4 tumour and a 5583-S tumour
in the right and left thighs, respectively. Imaging of the M04
1-4 tumour by intact 17E3 at day 6 is shown in Figure 4a.
Antibody 7F produced a clear image of the CEA-expressing
tumour on days 10 and 13 (Figure 4b). The negative controls
(antigen-negative tumour; non-specific antibodies) confirmed
the specificity of the tumour imaging.
Upon injection of 1251I-labelled F(ab')2 fragments, scinti-
graphic images were obtained from 16 to 39 h after injection.
These images showed a reduction in blood pool radioactivity
in normal tissues and in the control tumour as compared
with intact antibodies. The 7E8 F(ab')2 fragments were pre-IMMUNOLOCALISATION OF PLAP-TRANSFECTED M04 TUMOURS
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Figure 3 Selective tumour uptake (SI) of 7E8 F(ab')2 fragments at different time points after injection of this antibody fragment
(note the logarithmic scale on, the Y-axis). Results are expressed as tumour/non-tumour tissue ratios, calculated for both the target
tumour and the internal control tumour. The SI were separated determined for intestines (i), liver (ii), spleen (s), heart (h), lung
(lu), muscle (m), bone (b), and fat tissue (f). Also the SI found for kidneys (k) is indicated, although this was not included in the
calculation of the geometric mean. 0, M04 1-4 tumour; 0, 5583-S tumour; bar, geometric mean; *, P<0.05; ***, P<0.001.
Figure 4 Whole body scintigraphic images of athymic nude mice bearing s.c. M04 1-4 tumours on the right thigh, and 5583-S
tumours on the left thigh, given i.p. injections of 150pCi of 1251 labelled 17E3 IgG a, 7F IgG b, 7E8 F(ab')2 fragments c, or OKT3
F(ab')2 fragments d. Ventral images are shown at the most appropriate time points i.e. on day 6 a, day 13 b, at 39 h c, and 36 h d, after antibody injection. For every group, the size of both tumours was comparable.
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ferentially retained in the PLAP-expressing M04 1-4 tumour
(Figure 4c), and another high activity spot was possibly the
stomach (Andrew et al., 1986). The OKT3 F(ab')2 fragments
did not show any preferential uptake (Figure 4d). At the end
of these scannings, the mice were dissected and tissue
radioactivity was counted. The biodistribution results in these
mice were very similar to those from the biodistribution
experiments described above (data not shown): at 39 h after
injection, the mean tumour (MO4 1-4)/non-tumour tissue
ratios for the mouse injected with 7E8 F(ab')2 or with OKT3
F(ab')2 were 15.6 and 1.4, respectively. Similar ratios for the
control (5583-S) tumour were 1.7 and 1.3, respectively.
Discussion
In this study we describe a novel in vivo model for immuno-
targeting of PLAP-presenting tumours, grown in the thighs
of nude mice bearing size-matched control tumours grown in
the opposite thigh. M04 1-4 cells were derived from the
virally transformed murine M04 fibroblast cells upon trans-
fection with a cDNA of human PLAP (type 2). The tumour
incidence (100%), latency times, and tumour growth curves
found for transfected M04 1-4 cells were similar to results
obtained for nontransfected M04 cells which have been
documented previously (Mareel et al., 1975; Meyvisch &
Mareel, 1982). Our detailed characterisation of the PLAP
synthesised by the M04 1-4 cells confirmed that all enzy-
matic and immunologic properties were conserved, and that
it was localised on the outer surface of the plasma membrane
of these M04 1-4 cells, making it an ideal target for tumour
localisation and imaging. Most significantly, PLAP synthesis
by M04 1-4 cells was found to be stable during passage in
nude mice. This made the transfected M04 1-4 cells a prefer-
red model over previously described PLAP-models based on
Hela cells, which were subject to a 50-60% loss of PLAP
expression during passage in nude mice (Jeppsson et al.,
1984).
Theoretically, if two idiotypic antibodies with different
affinity constants are targeted to the same tumour-associated
antigen, the one with the highest affinity should lead to
higher selective tumour uptake and better scintigraphic
images. However, other factors than in vitro binding activities
can also influence tumour lcoalisation in vivo. For instance,
heterogeneity of the antigen expression and the context of
antigen-presentation on the tumour cells, as well as vascular
permeability in the tumour may be of importance in anti-
body-mediated tumour localisation. Moreover, it has been
shown that normal immunoglobulins, labelled with radioiso-
topes and injected in experimental animals, accumulate to a
larger extent in tumour xenografts than in normal tissues
(Bale et al., 1980). This has been explained by the disorgan-
ised cellular growth in tumours, causing impaired lymphatic
drainage of non-specific IgG leaked into the larger interstitial
tumour space. Furthermore, the antibody subclass (Eccles et
al., 1989), type of radionuclide (Sakahara et al., 1988), as
well as the labelling method and labelling efficiency (Matzku
et al., 1985; Pimm & Baldwin, 1987b) have all been shown to
alter biodistribution and tumour targeting capabilities of
monoclonal antibodies.
Appropriate experimental conditions to exclude non-specific
trapping of antibodies in tumour tissue or differences in
organ uptake due to subclass specificity were developed in a
two-tumour/two-antibody system using size-matched PLAP-
positive vs internal control tumours, and PLAP-specific vs
non-specific monoclonal antibodies of the same IgGI subclass
(except for the OKT3 fragments). In this system, we com-
pared the in vivo tumour localisation ability of two radio-
iodinated intact monoclonal antibodies, 7E8 and 17E3, with
high specificities for PLAP and well-defined in vitro immuno-
reactivities, but with affinity constants of 9 x 108M- and
0.9 X 108 M'l, respectively (De Broe & Pollet, 1988; Hendrix
et al., 1990). Live cell-binding, EAIA, and indirect immuno-
fluorescence studies confirmed higher PLAP binding by 7E8
than by 17E3 in vitro. Since caution is necessary when
radiolabelling antibodies to high specific activities (Pimm &
Baldwin, 1985; Pimm & Baldwin, 1987b), we controlled
affinity and immunoreactivity of the purified labelled anti-
bodies to ensure that labelling conditions had not affected
their immunological functions. Biodistribution data showed,
however, that no selective tumour uptake, specific tumour
localisation, or clear tumour imaging were obtained with the
highest affinity intact antibody 7E8. With 17E3 only a limited
accumulation of radioactivity in the PLAP-positive tumour
was noted (elevated AUC value). Absolute uptake by the
M04 1-4 tumour was complete after about 24 h (5.0 ± 0.6%
of injected dose/g tumour). The satisfactory images obtained
for this low affinity antibody could be attributed to the
selectivity of localisation (maximal mean SI = 4.8).
A clear retention of antibody in antigen-expressing tumour
was observed when the CEA-positive 5583-S tumour was
considered as the tumour ofinterest, with anti-CEA antibody
7F as the specific, and 17E3 as the non-specific antibody.
This preferential tumour retention was in agreement with
good SI and LI values (maximal values were 12.9 and 4.5,
respectively). Selective and specific tumour localisation, as
well as clear gamma camera imaging was achieved, confirm-
ing earlier findings for CEA-positive tumour targeting with
intact antibodies (Hedin et al., 1982; Buchegger et al., 1983;
Pimm et al., 1989).
In spite of apparently favourable antigen and antibody
characteristics of the PLAP/anti-PLAP system, selectivity and
specificity of tumour localisation using intact antibodies was
poor. It has been reported that affinity and specificity of
binding in vitro do not necessarily predict selectivity and
specificity of uptake in vivo (Mann et al., 1984; Sakahara et
al., 1988). Since antibody binding to Fc receptors may contri-
bute to the low selectivity of antibody accumulation in
tumours, improved tumour-to-background ratios can be
achieved by the use of F(ab')2 or Fab fragments. In several
studies, the use of such fragments resulted in images superior
to those from intact antibodies (Buchegger et al., 1983; Wahl
et al., 1983; Herlyn et al., 1983; Durbin et al., 1988). Fab
fragments were omitted from this study since they are report-
ed to be inferior to F(ab')2 fragments and unsuitable for use
in patients due to their low absolute tumour uptake, very
high clearance rates, and in vivo instability (Wahl et al., 1983;
Durbin et al., 1988).
The production of F(ab')2 fragments, however, may be
hampered because of the unpredictability of pepsin digestion
(Mather et al., 1987; Lamoyi & Nisonoff, 1983; Durbin et al.,
1988). In our hands, pepsin digestion of the antibodies pro-
ved satisfactory for 7E8 and OKT3 only. The latter antibody
is of the IgG2a subclass, but blood clearance rates for 7E8
F(ab')2 and OKT3 F(ab')2 were similar and no preferential
uptake in any tissue was seen for the OKT3 F(ab')2 fragment,
making it suitable as a non-specific control for 7E8 F(ab')2.
Although labelled 7E8 and its F(ab')2 fragment had com-
parable affinities for purified PLAP and for PLAP in vitro on
the cell surface, the F(ab')2 fragments had quite different
biodistribution and tumour localisation properties as com-
pared with results for intact antibody. In accordance with
earlier reports (Buchsbaum et al., 1988; Durbin et al., 1988),
we found that F(ab')2 fragments were cleared more rapidly
from blood than intact antibody, with a catabolic phase
half-life of 4 to 5 h, as compared with 62 to 107 h for intact
antibodies. Elimination rates of 7E8 F(ab')2 fragments from
control tumour and non-tumour tissue were much higher
than from the PLAP-positive tumour. The uptake of 7E8
F(ab')2 fragments was only elevated in the kidney, which is
known as a major site of fragment catabolism in mice (Covell
et al., 1986). It has been reported that F(ab')2 fragments have
reduced absolute tumour uptake compared with intact IgG
(Buchegger et al., 1983; Blumenthal et al., 1989; Sharkey et
al., 1990). However, we found that peak levels of F(ab')2
fragments in antigen-expressing tumour (at about 7.5% of
injected dose/g, 2 h after injection) were even higher than
those found for intact antibodies. Thereafter, the level of
fragments declined faster than that of intact antibody. It has
been thought that intra-tumour catabolism offragments pro-IMMUNOLOCALISATION OF PLAP-TRANSFECTED M04 TUMOURS 1067
ceeds faster than catabolism of intact antibodies (Pimm &
Baldwin, 1987a; Endo et al., 1987; Pimm et al., 1989).
When selective tumour localisation was expressed as
tumour to non-tumour tissue ratio, 7E8 F(ab')2 fragments
scored about 12 times better than intact 7E8 and seven times
better than intact 17E3 (mean geometric SI was 34.5 at 46 h).
In addition, tumour localisation by 7E8 F(ab')2 fragments
was highly specific with a localisation index of 29.0 at 46 h.
As expected, excellent imaging of M04 1-4 tumours with 7E8
F(ab')2 fragments was obtained upon gamma camera recor-
ding. These results complement the earlier findings obtained
for localisation of HeLa cell tumours via the PLAP/anti-
PLAP system with polyclonal or monoclonal antibodies (Jep-
psson et al., 1984) and antibody fragments (Durbin et al.,
1988; Stigbrand et al., 1989), although the latter authors
report a higher efficiency for intact antibodies than for
F(ab')2 fragments.
In conclusion, we can state that (1) recombinant M04 1-4
tumours grown in the thighs ofnude mice are a useful in vivo
model for tumour immuno-targeting due to their stable ex-
pression of PLAP on the plasma membrane; (2) it is possible
to discriminate PLAP-expressing tumours in nude mice,
using a 125I-labelled monoclonal antibody with a rather low
affinity for PLAP (17E3); and (3) excellent selective and
specific immunolocalisation and high imaging efficiency of
the same tumours is achieved upon injection of F(ab')2 frag-
ments of the high affinity 7E8 antibody which, when injected
as intact antibody, did not result in meaningful tumour
localisation.
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